Foghorn Therapeutics To Present At Upcoming Conferences Including New Preclinical Data From EP300 And CBP Selective Degrader Programs
Portfolio Pulse from Benzinga Newsdesk
Foghorn Therapeutics Inc. (NASDAQ:FHTX) will present new data from multiple preclinical and clinical programs at the 6th Annual Targeted Protein Degradation (TPD) Summit and the Connective Tissue Oncology Society (CTOS) Annual Meeting. The company will present data from its selective EP300 and CBP degrader programs, and preliminary results from a Phase 1 study of FHD-609, a bromodomain-containing protein 9 degrader.
October 24, 2023 | 12:14 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Foghorn Therapeutics is set to present new data from its preclinical and clinical programs, which could potentially impact the company's stock depending on the results.
The presentation of new data from Foghorn Therapeutics' programs could potentially impact the company's stock. Positive results could increase investor confidence and drive the stock price up, while negative results could have the opposite effect. However, without knowing the specifics of the data to be presented, it's difficult to predict the exact impact.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100